Taiwan Liposome Gets the Go-Ahead for a Hydroxychloroquine COVID-19 Study

Paula Bronstein / Getty Images News via Getty ImagesTaiwan Liposome Co. Ltd. (NASDAQ: TLC) shares shot up on Wednesday after the firm announced that it would be able to move forward with its COVID-19 trial that uses hydroxychloroquine. In the past, hydroxychloroquine has been viewed as a controversial drug in terms of evaluating its efficacy in treating COVID-19, but now there seems to be a definitive ruling on it—at least in Australia and Taiwan.

In terms of the specifics, the company announced the receipt of ethical and scientific approval from the Bellberry Human Research Ethics Committee (HREC) in Australia for the company’s Phase 1 clinical trial of TLC19 hydroxychloroquine liposome inhalation suspension for COVID-19.

The HREC is constituted in accordance with the requirements of the National Health & Medical Research Council (NHMRC), and it reviews clinical trial proposals to ensure that they are ethically and scientifically acceptable and have

Read More
Read More